Literature DB >> 30420071

Management of Early-Stage Melanoma.

Maria J Quintanilla-Dieck1, Christopher K Bichakjian2.   

Abstract

Melanoma is a potentially aggressive skin cancer with a steadily rising incidence. Most melanomas are diagnosed at an early stage and associated with an excellent prognosis when treated appropriately. Primary treatment for melanoma is surgical. Wider surgical margins and a variety of techniques for comprehensive histologic margin assessment may be considered for lentigo maligna type melanoma on the head and neck, due to characteristic broad subclinical extension. For invasive melanoma, sentinel lymph node biopsy may be indicated for staging, and to guide further management and follow-up. Appropriate treatment guidelines for early-stage melanoma are reviewed and discussed.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lentigo maligna; Melanoma; Melanoma in situ; Sentinel lymph node biopsy

Mesh:

Year:  2019        PMID: 30420071     DOI: 10.1016/j.fsc.2018.08.003

Source DB:  PubMed          Journal:  Facial Plast Surg Clin North Am        ISSN: 1064-7406            Impact factor:   1.918


  3 in total

1.  Combined Therapy with Dacarbazine and Hyperthermia Induces Cytotoxicity in A375 and MNT-1 Melanoma Cells.

Authors:  Diana Salvador; Verónica Bastos; Helena Oliveira
Journal:  Int J Mol Sci       Date:  2022-03-25       Impact factor: 5.923

2.  A simple electrochemical immunosensor based on a chitosan/reduced graphene oxide nanocomposite for sensitive detection of biomarkers of malignant melanoma.

Authors:  Huihua Zhang; Hui Qu; Jingbo Cui; Linxia Duan
Journal:  RSC Adv       Date:  2022-09-12       Impact factor: 4.036

3.  A network pharmacology approach to evaluate the synergistic effect of dihydromyricetin and myricitrin in vine tea on the proliferation of B16F10 cells.

Authors:  Nanxing Zhao; Hongming Kong; Hesheng Liu; Qing Shi; Xiangyang Qi; Qiuping Chen
Journal:  Front Nutr       Date:  2022-09-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.